Get the Stockscreener App
12.76
7.55%
-1.195
Neuropace Inc stock is traded at $12.76, with a volume of 51,013.
It is down -7.55% in the last 24 hours and down -16.74% over the past month.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.
See More
Previous Close:
$13.95
Open:
$13.49
24h Volume:
51,013
Relative Volume:
0.25
Market Cap:
$420.01M
Revenue:
$65.42M
Net Income/Loss:
$-32.96M
P/E Ratio:
-10.04
EPS:
-1.27
Net Cash Flow:
$-19.87M
1W Performance:
-14.14%
1M Performance:
-16.74%
6M Performance:
+32.55%
1Y Performance:
+10.89%
1-Day Range:
$12.61
$13.49
1-Week Range:
$12.85
$15.71
52-Week Range:
$7.5625
$18.98
Neuropace Inc Stock (NPCE) Company Profile
Name
Neuropace Inc
Sector
Industry
Phone
(650) 237-2700
Address
455 N. BERNARDO AVENUE, MOUNTAIN VIEW
Compare NPCE vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
12.61 | 464.64M | 65.42M | -32.96M | -19.87M | -1.27 |
|
ABT
Abbott Laboratories
|
111.62 | 196.53B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
375.79 | 146.14B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
93.55 | 122.74B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
71.54 | 107.15B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
84.63 | 49.45B | 6.07B | 1.06B | 1.34B | 1.8063 |
Neuropace Inc Stock (NPCE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-25 | Initiated | H.C. Wainwright | Buy |
| Jan-21-25 | Initiated | UBS | Buy |
| Mar-14-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-30-24 | Initiated | Leerink Partners | Outperform |
| Nov-10-23 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-24-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-22-23 | Initiated | Lake Street | Buy |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Jan-19-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-07-22 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-11-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-18-21 | Initiated | Robert W. Baird | Outperform |
| May-17-21 | Initiated | JP Morgan | Overweight |
| May-17-21 | Initiated | Morgan Stanley | Overweight |
| May-17-21 | Initiated | SVB Leerink | Outperform |
| May-17-21 | Initiated | Wells Fargo | Overweight |
View All
Neuropace Inc Stock (NPCE) Latest News
NeuroPace (NASDAQ:NPCE) Stock Rating Upgraded by Cantor Fitzgerald - MarketBeat
Neuropace (NPCE) chief medical officer sells $399k in stock - Investing.com
Regulatory Shutdowns Threaten Neuropace’s FDA Approvals and Capital Market Access - TipRanks
NeuroPace (NPCE) Loss Narrowing In Q4 Tests Bullish Profitability Narrative - simplywall.st
NeuroPace (NPCE) CMO sells shares under Rule 10b5-1 trading plan - Stock Titan
NeuroPace (NPCE) CEO reports 5,023-share tax-withholding disposition on RSU vesting - Stock Titan
Why NeuroPace Stock Was Inching Higher on Wednesday - AOL.com
Why NeuroPace Stock Was Inching Higher on Wednesday - The Motley Fool
NeuroPace (NPCE) Q4 2025 Earnings Call Transcript - The Globe and Mail
NeuroPace Q4 Earnings Call Highlights - MarketBeat
NeuroPace Beats Q1 Earnings Estimates - National Today
NeuroPace, Inc. (NPCE) Reports Q4 Loss, Beats Revenue Estimates - Nasdaq
Neuropace earnings beat by $0.10, revenue topped estimates - Investing.com Canada
NeuroPace : Investor Presentation - marketscreener.com
NeuroPace reports $99.99M revenue, $(0.66) EPS in 10-K - TradingView
NeuroPace Q4 Loss Narrows, Revenue Rises; Shares Gain After Hours - marketscreener.com
NeuroPace (NASDAQ:NPCE) Issues Earnings Results, Beats Estimates By $0.08 EPS - MarketBeat
NeuroPace (NPCE) outlines RNS growth, trials and capital moves in 10-K - Stock Titan
NeuroPace Inc.: Fourth Quarter Earnings Overview - Bitget
Neuropace Inc. (NPCE) Stock Rises on Q4 2025 Earnings - Quiver Quantitative
Press Release: NeuroPace Reports First Quarter 2025 Financial Results - 富途牛牛
NeuroPace beats estimates as Q4 revenue surges 24%, sending shares up 15% - Investing.com South Africa
NeuroPace beats estimates as Q4 revenue surges 24%, sending shares up 15% By Investing.com - Investing.com Canada
NeuroPace Inc.: Q4 Earnings Snapshot - marketscreener.com
NeuroPace (NASDAQ: NPCE) posts 25% 2025 growth and sets 2026 revenue, margin guidance - Stock Titan
Earnings Summary: NeuroPace Q4 - Benzinga
NeuroPace, Inc. Reiterates Earnings Guidance for the first quarter and full year of 2026 - marketscreener.com
NPCE Earnings History & Surprises | EPS & Revenue Results | NEUROPACE INC (NASDAQ:NPCE) - ChartMill
NeuroPace (NPCE) CEO covers RSU taxes through 1,126-share withholding - Stock Titan
NeuroPace Inc RNS System reduces seizure frequency in epilepsy patient Brian - Traders Union
NeuroPace (NPCE) CMO has 358 shares withheld for RSU tax - Stock Titan
Earnings Outlook For NeuroPace - Benzinga
NeuroPace Inc (NPCE) Q4 2025: Everything You Need To Know Ahead Of Earnings - GuruFocus
NPCE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Should You Buy Neuropace Inc (NPCE) Today? Analysis, Price Targets, and 2026 Outlook. - Intellectia AI
Neuropace Inc expected to post a loss of 15 cents a shareEarnings Preview - TradingView
Neuropace, Inc. (NPCE) Investor Outlook: Strong Buy Ratings and a 29.83% Upside Potential - DirectorsTalk Interviews
Earnings Preview: NeuroPace to Report Financial Results Post-market on March 03 - 富途牛牛
(NPCE) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
NeuroPace Q4: Has the Market Already Factored in the Results? - Bitget
NeuroPace, Inc. (NPCE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Finviz
NeuroPace (NPCE) Projected to Post Earnings on Tuesday - MarketBeat
NeuroPace (NPCE) CMO has shares withheld to cover RSU taxes - Stock Titan
NeuroPace to Report Fourth Quarter 2025 Financial Results on March 3, 2026 - Business Wire
Brain Implants Market to Reach USD 10.8 Billion by 2030 Growing - openPR.com
What’s the analyst consensus on NeuroPace Inc.Portfolio Update Report & Capital Efficient Trading Techniques - mfd.ru
How (NPCE) Movements Inform Risk Allocation Models - Stock Traders Daily
NPCE PE Ratio & Valuation, Is NPCE Overvalued - Intellectia AI
Neuropace, Inc. (NPCE) Stock Analysis: A 34% Potential Upside Sparks Investor Interest - DirectorsTalk Interviews
Is NeuroPace Inc. stock a dividend growth opportunity2025 Retail Activity & Consistent Income Trade Recommendations - mfd.ru
Essex Investment Management Co. LLC Raises Holdings in NeuroPace, Inc. $NPCE - MarketBeat
Neuropace Inc Stock (NPCE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.60%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):